Clinical utility of microarrays

Current status, existing challenges and future outlook

Xinmin Li, Richard J. Quigg, Jian Zhou, Weikuan Gu, P. Nagesh Rao, Elaine F. Reed

Research output: Contribution to journalReview article

50 Citations (Scopus)

Abstract

Microarray-based clinical tests have become powerful tools in the diagnosis and treatment of diseases. In contrast to traditional DNA-based tests that largely focus on single genes associated with rare conditions, microarray-based tests are ideal for the study of diseases with underlying complex genetic causes. Several microarray based tests have been translated into clinical practice such as MammaPrint and AmpliChip CYP450. Additional cancer-related microarray-based tests are either in the process of FDA review or under active development, including Tissue of Tumor Origin and Ampli-Chip p53. All diagnostic microarray testing is ordered by physicians and tested by a Clinical Laboratories Improvement Amendment-certified (CLIA) reference laboratory. Recently, companies offering consumer based microarray testing have emerged. Individuals can order tests online and service providers deliver the results directly to the clients via a password-protected secure website. Navigenics, 23andMe and deCODE Genetics represent pioneering companies in this field. Although the progress of these microarray-based tests is extremely encouraging with the potential to revolutionize the recognition and treatment of common diseases, these tests are still in their infancy and face technical, clinical and marketing challenges. In this article, we review microarray-based tests which are currently approved or under review by the FDA, as well as the consumer-based testing. We also provide a summary of the challenges and strategic solutions in the development and clinical use of the microarray-based tests. Finally, we present a brief outlook for the future of microarray-based clinical applications.

Original languageEnglish (US)
Pages (from-to)466-474
Number of pages9
JournalCurrent Genomics
Volume9
Issue number7
DOIs
StatePublished - Jan 1 2008

Fingerprint

Marketing
Neoplasms
Physicians
DNA
Therapeutics
Genes

All Science Journal Classification (ASJC) codes

  • Genetics
  • Genetics(clinical)

Cite this

Clinical utility of microarrays : Current status, existing challenges and future outlook. / Li, Xinmin; Quigg, Richard J.; Zhou, Jian; Gu, Weikuan; Nagesh Rao, P.; Reed, Elaine F.

In: Current Genomics, Vol. 9, No. 7, 01.01.2008, p. 466-474.

Research output: Contribution to journalReview article

Li, Xinmin ; Quigg, Richard J. ; Zhou, Jian ; Gu, Weikuan ; Nagesh Rao, P. ; Reed, Elaine F. / Clinical utility of microarrays : Current status, existing challenges and future outlook. In: Current Genomics. 2008 ; Vol. 9, No. 7. pp. 466-474.
@article{d88213096b2f48d2b84c8b9fcd11059d,
title = "Clinical utility of microarrays: Current status, existing challenges and future outlook",
abstract = "Microarray-based clinical tests have become powerful tools in the diagnosis and treatment of diseases. In contrast to traditional DNA-based tests that largely focus on single genes associated with rare conditions, microarray-based tests are ideal for the study of diseases with underlying complex genetic causes. Several microarray based tests have been translated into clinical practice such as MammaPrint and AmpliChip CYP450. Additional cancer-related microarray-based tests are either in the process of FDA review or under active development, including Tissue of Tumor Origin and Ampli-Chip p53. All diagnostic microarray testing is ordered by physicians and tested by a Clinical Laboratories Improvement Amendment-certified (CLIA) reference laboratory. Recently, companies offering consumer based microarray testing have emerged. Individuals can order tests online and service providers deliver the results directly to the clients via a password-protected secure website. Navigenics, 23andMe and deCODE Genetics represent pioneering companies in this field. Although the progress of these microarray-based tests is extremely encouraging with the potential to revolutionize the recognition and treatment of common diseases, these tests are still in their infancy and face technical, clinical and marketing challenges. In this article, we review microarray-based tests which are currently approved or under review by the FDA, as well as the consumer-based testing. We also provide a summary of the challenges and strategic solutions in the development and clinical use of the microarray-based tests. Finally, we present a brief outlook for the future of microarray-based clinical applications.",
author = "Xinmin Li and Quigg, {Richard J.} and Jian Zhou and Weikuan Gu and {Nagesh Rao}, P. and Reed, {Elaine F.}",
year = "2008",
month = "1",
day = "1",
doi = "10.2174/138920208786241199",
language = "English (US)",
volume = "9",
pages = "466--474",
journal = "Current Genomics",
issn = "1389-2029",
publisher = "Bentham Science Publishers B.V.",
number = "7",

}

TY - JOUR

T1 - Clinical utility of microarrays

T2 - Current status, existing challenges and future outlook

AU - Li, Xinmin

AU - Quigg, Richard J.

AU - Zhou, Jian

AU - Gu, Weikuan

AU - Nagesh Rao, P.

AU - Reed, Elaine F.

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Microarray-based clinical tests have become powerful tools in the diagnosis and treatment of diseases. In contrast to traditional DNA-based tests that largely focus on single genes associated with rare conditions, microarray-based tests are ideal for the study of diseases with underlying complex genetic causes. Several microarray based tests have been translated into clinical practice such as MammaPrint and AmpliChip CYP450. Additional cancer-related microarray-based tests are either in the process of FDA review or under active development, including Tissue of Tumor Origin and Ampli-Chip p53. All diagnostic microarray testing is ordered by physicians and tested by a Clinical Laboratories Improvement Amendment-certified (CLIA) reference laboratory. Recently, companies offering consumer based microarray testing have emerged. Individuals can order tests online and service providers deliver the results directly to the clients via a password-protected secure website. Navigenics, 23andMe and deCODE Genetics represent pioneering companies in this field. Although the progress of these microarray-based tests is extremely encouraging with the potential to revolutionize the recognition and treatment of common diseases, these tests are still in their infancy and face technical, clinical and marketing challenges. In this article, we review microarray-based tests which are currently approved or under review by the FDA, as well as the consumer-based testing. We also provide a summary of the challenges and strategic solutions in the development and clinical use of the microarray-based tests. Finally, we present a brief outlook for the future of microarray-based clinical applications.

AB - Microarray-based clinical tests have become powerful tools in the diagnosis and treatment of diseases. In contrast to traditional DNA-based tests that largely focus on single genes associated with rare conditions, microarray-based tests are ideal for the study of diseases with underlying complex genetic causes. Several microarray based tests have been translated into clinical practice such as MammaPrint and AmpliChip CYP450. Additional cancer-related microarray-based tests are either in the process of FDA review or under active development, including Tissue of Tumor Origin and Ampli-Chip p53. All diagnostic microarray testing is ordered by physicians and tested by a Clinical Laboratories Improvement Amendment-certified (CLIA) reference laboratory. Recently, companies offering consumer based microarray testing have emerged. Individuals can order tests online and service providers deliver the results directly to the clients via a password-protected secure website. Navigenics, 23andMe and deCODE Genetics represent pioneering companies in this field. Although the progress of these microarray-based tests is extremely encouraging with the potential to revolutionize the recognition and treatment of common diseases, these tests are still in their infancy and face technical, clinical and marketing challenges. In this article, we review microarray-based tests which are currently approved or under review by the FDA, as well as the consumer-based testing. We also provide a summary of the challenges and strategic solutions in the development and clinical use of the microarray-based tests. Finally, we present a brief outlook for the future of microarray-based clinical applications.

UR - http://www.scopus.com/inward/record.url?scp=60849126175&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60849126175&partnerID=8YFLogxK

U2 - 10.2174/138920208786241199

DO - 10.2174/138920208786241199

M3 - Review article

VL - 9

SP - 466

EP - 474

JO - Current Genomics

JF - Current Genomics

SN - 1389-2029

IS - 7

ER -